← Leaderboards
Alan L Mueller
Navigen, Inc.
$15,252,253
Attributed
$17,727,101
Total exposure
16
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2010–22$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$17,727,101 · 16
By mechanism
R44$5,341,042 · 3
SB1$3,000,000 · 1
U44$3,000,000 · 1
R01$2,817,486 · 2
R43$2,233,685 · 7
R56$1,334,888 · 2
Top collaborators
- Brett D Welch3 shared
- Daniel A Wettstein3 shared
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseCessation Of LifeDrug KineticsInhibitor/AntagonistToxicologyIn VivoInfectionPharmaceutical PreparationsCenters For Disease Control And Prevention (U.S.)Clinical TrialsSmall Business Innovation Research GrantSafetyLifeLeadHiv Entry InhibitorsPeptide HydrolasesPropertyAids/Hiv ProblemAcquired Immunodeficiency SyndromeEpidemicDrug ResistancePeptidesResistanceFunding
Grant awards (27)
A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV$1,000,000
U44 · FY2022 · AI · contact PI
A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV$1,000,000
U44 · FY2021 · AI · contact PI
A Phase Ia/Ib Clinical Study of HIV Entry Inhibitor CPT31:Single and Multiple Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Adults anAdults with HIV$1,000,000
U44 · FY2020 · AI · contact PI
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
SB1 · FY2019 · AI · contact PI
Depot formulation of a D-peptide HIV entry inhibitor$551,835
R01 · FY2019 · AI · contact PI
Stabilization of the Alveolar-Capillary Barrier with ARF6 Inhibitor as a Treatment for Severe Influenza$268,075
R43 · FY2019 · HL · contact PI
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
SB1 · FY2018 · AI · contact PI
ARF6 Inhibitors for Treatment of Acute Lung Injury$817,279
R44 · FY2018 · HL · contact PI
Depot formulation of a D-peptide HIV entry inhibitor$571,590
R01 · FY2018 · AI · contact PI
ARF6 Inhibitor as Adjunctive Therapy for Treatment of SA Bacteremia$300,000
R43 · FY2018 · AI · contact PI
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
SB1 · FY2017 · AI · contact PI
ARF6 Inhibitors for Treatment of Acute Lung Injury$889,461
R44 · FY2017 · HL · contact PI
Depot formulation of a D-peptide HIV entry inhibitor$826,272
R01 · FY2017 · AI · contact PI
Depot formulation of a D-peptide HIV entry inhibitor$524,908
R56 · FY2016 · AI · contact PI
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
R44 · FY2015 · AI · contact PI
Arf6 inhibitors for the treatment of uveal melanoma$298,731
R43 · FY2015 · CA · contact PI
Developing a Peripherally-Acting Peptidic Galanin Analog for Treatment of Postoperative Pain$290,919
R43 · FY2015 · DA · contact PI
Treating Acute Lung Injury via Cytokine Signaling Blockade$224,632
R43 · FY2015 · HL · contact PI
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
R44 · FY2014 · AI · contact PI
Therapeutic D-peptide Inhibitor of HIV Entry$1,000,000
R44 · FY2013 · AI · contact PI
Slit2N for the Treatment of Viral Hemorrhagic Fever$809,980
R56 · FY2012 · AI · contact PI
Preventing lethal hemorrhagic fever caused by hantaviruses by preserving endothel$351,045
R01 · FY2012 · AI · contact PI
Novel Therapeutic Approach for Sepsis: Blocking the Vascular Response to Cytokine$274,171
R43 · FY2012 · AI · contact PI
Preventing lethal hemorrhagic fever caused by hantaviruses by preserving endothel$516,744
R01 · FY2011 · AI · contact PI
Therapeutic D-peptide Inhibitor of HIV entry$299,392
R43 · FY2011 · AI · contact PI
Novel Therapeutic Approach for Sepsis: Blocking the Vascular Response to Cytokine$277,765
R43 · FY2011 · AI · contact PI
Anti-HTRA1 Therapy For AMD$634,302
R44 · FY2010 · EY · contact PI